Association study on the microRNA-1 target gene polymorphism and the risk of premature coronary artery disease

Chinese Journal of Cardiology

Volumn 40, Issue 5, 2012, Pages 386-391

  Zhang, Jia Ju ^a   Wang, Li Na ^b   Feng, Yi ^b   Zhi, Hong ^b   Ma, Gen Shan ^b   Ye, Xing Zhou ^b   Qian, Sha Sha ^b   Wang, Bei ^b  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b NONE

Author keywords

Case control studies; Coronary disease; MicroRNAs; Polymorphism, single nucleotide

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA 1; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE TARGETING; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PREMATURE CORONARY ARTERY DISEASE; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84864378659     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2012.05.007     Document Type: Article

References (18)

1. National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation, 2002, 106: 3143-3421.
2. Bartel, D P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116: 281-297.
3. Abelson J F, Kwan K Y, O'Roak B J, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science, 2005, 310: 317-320.
4. Sethupathy P, Collins F S. MicroRNA target site polymorphisms and human disease. Trends Genet, 2008, 24: 489-497.
5. Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clinical Science, 2010, 119: 87-95.
6. 2008, 36: 586-589.
7. 2007, 35: 390-413.
8. Puddu P, Cravero E, Puddu G M, et al. Genes and atherosclerosis: at the origin of the predisposition. Int J Clin Pract, 2005, 59: 462-472.
9. Griffiths-Jones S, Saini H K, van Dongen S, et al. miRBase: tools for microRNA genomics. Nucleic Acids Res, 2008, 36: 154-158.
10. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med, 2007, 13: 613-618.
11. Ivey K N, Muth A, Arnold J, et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell, 2008, 2: 219-229.
12. Ikeda S, He A, Kong S W, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Bio, 2009, 29: 2193-2204.
13. Xu C, Lu Y, Pan Z, et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci, 2007, 120 (Pt 17): 3045-3052.
14. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun, 2010, 391: 73-77.
15. D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J, 2010, 31: 2765-2773.
16. Xu J, Hu Z, Xu Z, et al. Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. Hum Mutat, 2009, 30: 1231-1236.
17. Zhou B, Rao L, Peng Y, et al. Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy. Clin Chim Acta, 2010, 411: 1287-1290.
18. Carr M C, Brunzell J D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab, 2004, 89: 2601-2607.